Viking Therapeutics (NASDAQ:VKTX) has been given a $23.00 target price by research analysts at Roth Capital in a report released on Friday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Roth Capital’s price objective would indicate a potential upside of 86.54% from the company’s previous close.

VKTX has been the subject of a number of other reports. SunTrust Banks assumed coverage on shares of Viking Therapeutics in a research report on Friday, July 20th. They issued a “buy” rating and a $14.00 price target for the company. Maxim Group reissued a “buy” rating and issued a $28.00 price target on shares of Viking Therapeutics in a research report on Thursday. BidaskClub cut shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 3rd. Raymond James set a $43.00 price target on shares of Viking Therapeutics and gave the company a “buy” rating in a research report on Wednesday, September 19th. Finally, William Blair reaffirmed a “market perform” rating on shares of Viking Therapeutics in a report on Monday, October 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Viking Therapeutics currently has a consensus rating of “Buy” and an average target price of $28.00.

Shares of VKTX opened at $12.33 on Friday. Viking Therapeutics has a 1-year low of $2.24 and a 1-year high of $24.00. The firm has a market capitalization of $851.64 million, a P/E ratio of -15.61 and a beta of 2.92.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. As a group, equities analysts predict that Viking Therapeutics will post -0.44 EPS for the current year.

In other news, major shareholder Ligand Pharmaceuticals Inc sold 262,881 shares of the company’s stock in a transaction dated Tuesday, September 25th. The shares were sold at an average price of $19.15, for a total value of $5,034,171.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.90% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Janney Montgomery Scott LLC purchased a new stake in shares of Viking Therapeutics in the second quarter valued at about $114,000. Strs Ohio purchased a new stake in shares of Viking Therapeutics in the second quarter valued at about $120,000. Cubist Systematic Strategies LLC purchased a new stake in shares of Viking Therapeutics in the second quarter valued at about $129,000. First Mercantile Trust Co. purchased a new stake in shares of Viking Therapeutics in the third quarter valued at about $131,000. Finally, State Board of Administration of Florida Retirement System purchased a new stake in shares of Viking Therapeutics in the second quarter valued at about $144,000. 53.56% of the stock is owned by institutional investors and hedge funds.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.

Featured Article: What is a Tariff?

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.